| Product Information | |
|---|---|
| Catalog#: | MK1268H |
| Product Name: | Recombinant Human PSMA Protein, His-tagged |
| Description: | Prostate-specific membrane antigen (PSMA) also known as Folate hydrolase 1 (FOLH1), Folylpoly-gamma-glutamate carboxypeptidase (FGCP), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), is a type II membrane glycoprotein that is expressed in prostate tissue and to a lesser extent in the peripheral and central nervous system, small intestinal, and salivary gland tissues. PSMA has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. The catalytic activity of PSMA involves the release of unsubstituted C-terminal glutamyl residues, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates. PSMA is used as a diagnostic and prognostic indicator of prostate cancer, and as a possible marker for various neurological disorders such as schizophrenia, Alzheimer’s disease, and Huntington’s disease. |
| Source: | CHO 3E7 cells |
| Species: | Human |
| Tag: | His |
| Formulation: | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Protein length: | Lys44-Ala750 |
| Purity: | > 85% as determined by SDS-PAGE. |
| Storage: | Store under sterile conditions at -20 °C to -80 °C. Avoid repeated freeze-thaw cycles. |
| Reconstitution: | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O or PBS up to 100 μg/mL. |
| Molecular Mass: | 90-120 kDa |
| Stability: | Upon receiving, this product remains stable for 6 months at lower than -70 °C. Upon reconstitution, the product should be stable for 1 week at 4 °C or for 3 months at -20 °C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. |
| Endotoxin: | < 1 EU/μg of protein by gel clotting method. |
| Notes: | Research Use Only. Not for use in clinical procedures. |
Enter your email here to subscribe